Table 2.
No. of subjects |
Test | Sensitivity (%) | Specificity (%) | Cross reaction | Year | Ref. | |||
CE patient | Other disease | Healthy control | |||||||
Ag5 | 39 | 51 | 29 | IgG ELISA | 54 | 89 | AE | 2000 | [9] |
Ag5 | 58 | 36 | 40 | IgG ELISA | 100 | 70.17 | Leish, Toxop, Fascio | 2006 | [39] |
Ag5 | 58 | 36 | 40 | IgG1 ELISA | 100 | 70.17 | Leish, Toxop, Fascio | 2006 | [38] |
Ag5 | 58 | 36 | 40 | IgG4 ELISA | 75.8 | 93.02 | Toxop, Fascio | 2006 | [38] |
Ag5 | 58 | 36 | 40 | IgE ELISA | 70.1 | 100 | None | 2006 | [38] |
rAg5 | 34 | 36 | 18 | IgG ELISA | 65 | 89 | AE, Cysts | 2005 | [77] |
rAg5-38s | 34 | 36 | 18 | IgG ELISA | 21 | 97 | AE | 2005 | [77] |
Leish: Leishmaniasis; Toxop: Toxoplasmosis; Fascio: Fascioliasis; Cysts: Cysticercosis; AE: Alveolar echinococcosis.